222 related articles for article (PubMed ID: 1629380)
1. A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder.
Pigott TA; L'Heureux F; Rubenstein CS; Bernstein SE; Hill JL; Murphy DL
J Clin Psychopharmacol; 1992 Jun; 12(3):156-62. PubMed ID: 1629380
[TBL] [Abstract][Full Text] [Related]
2. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder.
Chouinard G; Goodman W; Greist J; Jenike M; Rasmussen S; White K; Hackett E; Gaffney M; Bick PA
Psychopharmacol Bull; 1990; 26(3):279-84. PubMed ID: 2274626
[TBL] [Abstract][Full Text] [Related]
3. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy.
McDougle CJ; Price LH; Goodman WK; Charney DS; Heninger GR
J Clin Psychopharmacol; 1991 Jun; 11(3):175-84. PubMed ID: 1820757
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder.
McDougle CJ; Goodman WK; Leckman JF; Barr LC; Heninger GR; Price LH
J Clin Psychopharmacol; 1993 Oct; 13(5):354-8. PubMed ID: 8227493
[TBL] [Abstract][Full Text] [Related]
5. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine.
Tollefson GD; Birkett M; Koran L; Genduso L
J Clin Psychiatry; 1994 Oct; 55 Suppl():69-76; discussion 77-8. PubMed ID: 7961535
[TBL] [Abstract][Full Text] [Related]
6. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
[TBL] [Abstract][Full Text] [Related]
7. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder.
Sevincok L; Topuz A
J Clin Psychopharmacol; 2003 Oct; 23(5):448-50. PubMed ID: 14520120
[TBL] [Abstract][Full Text] [Related]
8. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder.
Pigott TA; Pato MT; L'Heureux F; Hill JL; Grover GN; Bernstein SE; Murphy DL
J Clin Psychopharmacol; 1991 Aug; 11(4):242-8. PubMed ID: 1918422
[TBL] [Abstract][Full Text] [Related]
9. Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients.
Greist JH; Jefferson JW; Rosenfeld R; Gutzmann LD; March JS; Barklage NE
J Clin Psychiatry; 1990 Jul; 51(7):292-7. PubMed ID: 2195006
[TBL] [Abstract][Full Text] [Related]
10. [Value of fluoxetine in obsessive-compulsive disorder in the adult: review of the literature].
Etain B; Bonnet-Perrin E
Encephale; 2001; 27(3):280-9. PubMed ID: 11488259
[TBL] [Abstract][Full Text] [Related]
11. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation.
Koran LM; Gamel NN; Choung HW; Smith EH; Aboujaoude EN
J Clin Psychiatry; 2005 Apr; 66(4):515-20. PubMed ID: 15816795
[TBL] [Abstract][Full Text] [Related]
12. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.
Freeman CP; Trimble MR; Deakin JF; Stokes TM; Ashford JJ
J Clin Psychiatry; 1994 Jul; 55(7):301-5. PubMed ID: 8071291
[TBL] [Abstract][Full Text] [Related]
13. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.
Munizza C; Olivieri L; Di Loreto G; Dionisio P
Curr Med Res Opin; 2006 Sep; 22(9):1703-13. PubMed ID: 16968574
[TBL] [Abstract][Full Text] [Related]
14. Obsessive compulsive disorder, depression, and fluoxetine.
Hollander E; Mullen L; DeCaria CM; Skodol A; Schneier FR; Liebowitz MR; Klein DF
J Clin Psychiatry; 1991 Oct; 52(10):418-22. PubMed ID: 1938978
[TBL] [Abstract][Full Text] [Related]
15. Symptoms and physiologic manifestations in obsessive compulsive patients before and after treatment with clomipramine.
Hoehn-Saric R; McLeod DR; Zimmerli WD; Hipsley PA
J Clin Psychiatry; 1993 Jul; 54(7):272-6. PubMed ID: 8335655
[TBL] [Abstract][Full Text] [Related]
16. Trazodone, a triazolopyridine derivative, in primary depressive disorder.
Feighner JP
J Clin Psychiatry; 1980 Jul; 41(7):250-5. PubMed ID: 6993447
[TBL] [Abstract][Full Text] [Related]
17. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results.
Pigott TA; Pato MT; Bernstein SE; Grover GN; Hill JL; Tolliver TJ; Murphy DL
Arch Gen Psychiatry; 1990 Oct; 47(10):926-32. PubMed ID: 2222131
[TBL] [Abstract][Full Text] [Related]
18. Trazodone, a new antidepressant: efficacy and safety in endogenous depression.
Kellams JJ; Klapper MH; Small JG
J Clin Psychiatry; 1979 Sep; 40(9):390-5. PubMed ID: 383704
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of the Hamilton Depression Rating Scale and the Self Rating Scale BS (v. Zerssen) within a double blind study on the antidepressant effects of trazodone verus amitriptyline (author's transl)].
Kieback D
Pharmacopsychiatria; 1982 May; 15(3):97-102. PubMed ID: 7100264
[TBL] [Abstract][Full Text] [Related]
20. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder.
Pigott TA; L'Heureux F; Hill JL; Bihari K; Bernstein SE; Murphy DL
J Clin Psychopharmacol; 1992 Feb; 12(1):11-8. PubMed ID: 1552034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
